Sorting through the many opportunities for melanoma therapy

Pigment Cell and Melanoma Research

Volumn 24, Issue 5, 2011, Pages 975-977

  Herlyn, Meenhard ^a   Villanueva, Jessie ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; SORAFENIB;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LETTER; MELANOMA; NONHUMAN; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HUMANS; IMMUNOTHERAPY; MELANOMA; MICE; MOLECULAR TARGETED THERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053905526     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2011.00906.x     Document Type: Letter

References (2)

1. Haass, N.K., Sproesser, K., Nguyen, T.K., Contractor, R., Medina, C.A., Nathanson, K.L., Herlyn, M., and Smalley, K.S.M. (2008). The MEK inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin. Cancer Res. 14, 230-239.
2. Herlyn, M., and Fukunaga-Kalabis, M. (2010). What is a good model for melanoma? J. Invest. Dermatol. 130, 911-912.